Olmesartan Krka (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension in adults.

GNH USA supplies Olmesartan Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Olmesartan medoxil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation

When prescribing Olmesartan Krka, clinicians should consider several safety aspects. - Pregnancy: cannot be used ; the risk of development issues for the fetus is high. - Breastfeeding: should be avoided if possible by the     g   t   ewline -   ewline

t  ewline   ewline  """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""" """